Treatment of severe hypercholesterolemia with a combination of beta-sitosterol and lovastatin

被引:16
作者
Richter, WO
Geiss, HC
Sonnichsen, AC
Schwandt, P
机构
[1] Department of Internal Medicine II, Klinikum Grosshadern, Munich
来源
CURRENT THERAPEUTIC RESEARCH-CLINICAL AND EXPERIMENTAL | 1996年 / 57卷 / 07期
关键词
D O I
10.1016/S0011-393X(96)80059-2
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
The objective of this study was to determine whether adding the plant sterol beta-sitosterol to a lipid-lowering treatment regimen of lovastatin further decreases low-density lipoprotein (LDL) cholesterol. Thirty patients (16 men, 14 women) with a mean age of 45 +/- 13 years, LDL cholesterol levels between 5.89 and 12.26 mmol/L, and triglyceride levels <2.82 mmoliL were randomly assigned to one of two study groups: group L (n = 15), which received lovastatin alone, and group LS (n = 15), which received lovastatin and beta-sitosterol. All patients were first treated for 16 weeks with the maximally tolerable dose of lovastatin. Beta-sitosterol 6 g/d was then added to the treatment regimen of group LS for 12 weeks, while group L continued with lovastatin alone. In the beta-sitosterol group, mean LDL cholesterol decreased by an additional 12.8% to 15.1%, a significant difference from the corresponding change in the group receiving lovastatin alone. After discontinuation of beta-sitosterol, LDL cholesterol increased again. The decrease in LDL and total cholesterol before the addition of beta-sitosterol was comparable in the two groups: the mean reduction in LDL cholesterol was 30.4% in group L and 25.8% in group LS; total cholesterol was decreased by 24.2% in group L and 21.1% in group LS. After the addition of beta-sitosterol, the total decrease in LDL cholesterol was 35.3% to 37.1%; the decrease in total cholesterol was 27.3% to 29.2%. No significant changes were observed in other lipid variables such as high-density lipoprotein cholesterol, lipoprotein(a), very-low-density lipoprotein triglycerides and cholesterol, apolipoprotein A-I, and lecithin-cholesterol acyltransferase activity.
引用
收藏
页码:497 / 505
页数:9
相关论文
共 16 条
[1]  
BECKER M, 1992, PEDIATRICS, V89, P138
[2]   MODIFICATION OF ABNORMAL SERUM LIPID PATTERNS IN ATHEROSCLEROSIS BY ADMINISTRATION OF SITOSTEROL [J].
BEST, MM ;
DUNCAN, CH .
ANNALS OF INTERNAL MEDICINE, 1956, 45 (04) :614-622
[3]   LOWERING OF SERUM CHOLESTEROL BY THE ADMINISTRATION OF A PLANT STEROL [J].
BEST, MM ;
DUNCAN, CH ;
VANLOON, EJ ;
WATHEN, JD .
CIRCULATION, 1954, 10 (02) :201-206
[4]   MEVINOLIN AND COLESTIPOL STIMULATE RECEPTOR-MEDIATED CLEARANCE OF LOW-DENSITY LIPOPROTEIN FROM PLASMA IN FAMILIAL HYPERCHOLESTEROLEMIA HETEROZYGOTES [J].
BILHEIMER, DW ;
GRUNDY, SM ;
BROWN, MS ;
GOLDSTEIN, JL .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA-BIOLOGICAL SCIENCES, 1983, 80 (13) :4124-4128
[5]   COMPARISON OF PROPERTIES OF 4 INHIBITORS OF 3-HYDROXY-3-METHYLGLUTARYL-COENZYME-A REDUCTASE [J].
BLUM, CB .
AMERICAN JOURNAL OF CARDIOLOGY, 1994, 73 (14) :D3-D11
[6]   EXPANDED CLINICAL-EVALUATION OF LOVASTATIN (EXCEL) STUDY RESULTS .1. EFFICACY IN MODIFYING PLASMA-LIPOPROTEINS AND ADVERSE EVENT PROFILE IN 8245 PATIENTS WITH MODERATE HYPERCHOLESTEROLEMIA [J].
BRADFORD, RH ;
SHEAR, CL ;
CHREMOS, AN ;
DUJOVNE, C ;
DOWNTON, M ;
FRANKLIN, FA ;
GOULD, AL ;
HESNEY, M ;
HIGGINS, J ;
HURLEY, DP ;
LANGENDORFER, A ;
NASH, DT ;
POOL, JL ;
SCHNAPER, H .
ARCHIVES OF INTERNAL MEDICINE, 1991, 151 (01) :43-49
[7]  
DANHOF IE, 1966, AM J CLIN NUTR, V18, P343
[8]  
HERNANDEZ HH, 1953, P SOC EXP BIOL MED, V83, P498, DOI 10.3181/00379727-83-20395
[9]   MEVINOLIN PLUS COLESTIPOL IN THERAPY FOR SEVERE HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA [J].
ILLINGWORTH, DR .
ANNALS OF INTERNAL MEDICINE, 1984, 101 (05) :598-604
[10]   EFFECTS OF LOVASTATIN ALONE AND IN COMBINATION WITH CHOLESTYRAMINE ON SERUM-LIPIDS AND APOLIPOPROTEINS IN HETEROZYGOTES FOR FAMILIAL HYPERCHOLESTEROLEMIA [J].
LEREN, TP ;
HJERMANN, I ;
BERG, K ;
LEREN, P ;
FOSS, OP ;
VIKSMOEN, L .
ATHEROSCLEROSIS, 1988, 73 (2-3) :135-141